Epidiolex

Latest articles

4d
FOX Business
These 6 Stocks Make Up 58% of the First-Ever Marijuana ETFs HoldingsGW Pharmaceuticals' (NASDAQ: GWPH) stock has performed of late. The company is
FOX Business / Posted 4 days ago
GW Pharmaceuticals' (NASDAQ: GWPH) stock has performed of late. The company is counting on success for its lead drug, Epidiolex, a cannabidiol-based oral medicine designed to treat two rare types of childhood-onset epilepsy, Dravet syndrome... Read more
4d
FOX Business
These 6 Stocks Make Up 58% of the First-Ever Marijuana ETFs HoldingsGW Pharmaceuticals' (NASDAQ: GWPH) stock has performed of late. The company is
FOX Business / Posted 4 days ago
GW Pharmaceuticals' (NASDAQ: GWPH) stock has performed of late. The company is counting on success for its lead drug, Epidiolex, a cannabidiol-based oral medicine designed to treat two rare types of childhood-onset epilepsy, Dravet syndrome... Read more
10d
Greeley Tribune
Race for CBD medication breakthrough: Is pharmaceutical firm’s boon the hemp industry’s doom?has caused some unease in the American hemp industry. London-based GW Pharmace
Greeley Tribune / Posted 10 days ago
has caused some unease in the American hemp industry. London-based GW Pharmaceuticals plc is steering its proprietary Epidiolex oral solution through the U.S. Food and Drug Administration's approval pipeline. Unlike other FDA-approved drugs... Read more
11d
FOX Business
This Potential Billion-Dollar Marijuana-Based Drug Suddenly Finds Itself in Deep TroubleGW Pharmaceuticals(NASDAQ: GWPH), the largest marijuana stock by market cap. GW
FOX Business / Posted 11 days ago
GW Pharmaceuticals(NASDAQ: GWPH), the largest marijuana stock by market cap. GW Pharmaceuticals' leading drug candidate is Epidiolex, an oral cannabidiol (CBD) solution designed to treat patients with two rare types of childhood-onset epilepsy,... Read more
11d
FOX Business
This Potential Billion-Dollar Marijuana-Based Drug Suddenly Finds Itself in Deep TroubleGW Pharmaceuticals(NASDAQ: GWPH), the largest marijuana stock by market cap. GW
FOX Business / Posted 11 days ago
GW Pharmaceuticals(NASDAQ: GWPH), the largest marijuana stock by market cap. GW Pharmaceuticals' leading drug candidate is Epidiolex, an oral cannabidiol (CBD) solution designed to treat patients with two rare types of childhood-onset epilepsy,... Read more
14d
FOX Business
Zogenix Soars 10% Today Despite Diluting Investorstreatments for epilepsy. GW Pharmaceuticals has reported positive phase 3 outc
FOX Business / Posted 14 days ago
treatments for epilepsy. GW Pharmaceuticals has reported positive phase 3 outcomes for its cannabidiol drug Epidiolex, in both Dravet syndrome and Lennox-Gastaut syndrome, and an FDA filing should happen soon. In its trials,... Read more
14d
FOX Business
Zogenix Soars 10% Today Despite Diluting Investorstreatments for epilepsy. GW Pharmaceuticals has reported positive phase 3 outc
FOX Business / Posted 14 days ago
treatments for epilepsy. GW Pharmaceuticals has reported positive phase 3 outcomes for its cannabidiol drug Epidiolex, in both Dravet syndrome and Lennox-Gastaut syndrome, and an FDA filing should happen soon. In its trials,... Read more
15d
FOX Business
This U.S. Marijuana Stock Is Arguably the Best on the Market -- and It's Dirt Cheapreview of where competitors are," a veiled reference to GW Pharmaceuticals, whi
FOX Business / Posted 15 days ago
review of where competitors are," a veiled reference to GW Pharmaceuticals, which is pursuing approval for its CBD product Epidiolex. Factoring in the pipeline potential could lead reasonable investors to conclude that Insys stock is dirt... Read more
15d
FOX Business
This U.S. Marijuana Stock Is Arguably the Best on the Market -- and It's Dirt Cheapreview of where competitors are," a veiled reference to GW Pharmaceuticals, whi
FOX Business / Posted 15 days ago
review of where competitors are," a veiled reference to GW Pharmaceuticals, which is pursuing approval for its CBD product Epidiolex. Factoring in the pipeline potential could lead reasonable investors to conclude that Insys stock is dirt... Read more
16d
FOX Business
3 Biotech Stocks That Soared This Week: Are They Buys?be catalysts. Zogenix appears to be headed for a battle with GW Pharmaceutical
FOX Business / Posted 16 days ago
be catalysts. Zogenix appears to be headed for a battle with GW Pharmaceuticals(NASDAQ: GWPH), which will soon submit Epidiolex for approval in treating both Dravet syndrome and Lennox-Gastault syndrome (LGS). Although GW Pharma stock dropped... Read more
3 related articles
16d
FOX Business
3 Biotech Stocks That Soared This Week: Are They Buys?be catalysts. Zogenix appears to be headed for a battle with GW Pharmaceutical
FOX Business / Posted 16 days ago
be catalysts. Zogenix appears to be headed for a battle with GW Pharmaceuticals(NASDAQ: GWPH), which will soon submit Epidiolex for approval in treating both Dravet syndrome and Lennox-Gastault syndrome (LGS). Although GW Pharma stock dropped... Read more
3 related articles
17d
FOX Business
A Tiny Biotech Just Dealt a Big Blow to Marijuana's Use in Epilepsyof the failed obesity drug fen-phen -- may control seizures in patients better
FOX Business / Posted 17 days ago
of the failed obesity drug fen-phen -- may control seizures in patients better than GW Pharmaceuticals's (NASDAQ: GWPH) Epidiolex, a highly anticipated marijuana-based drug. Targeting the toughest to treat Dravet syndrome is a rare and... Read more
17d
FOX Business
A Tiny Biotech Just Dealt a Big Blow to Marijuana's Use in Epilepsyof the failed obesity drug fen-phen -- may control seizures in patients better
FOX Business / Posted 17 days ago
of the failed obesity drug fen-phen -- may control seizures in patients better than GW Pharmaceuticals's (NASDAQ: GWPH) Epidiolex, a highly anticipated marijuana-based drug. Continue Reading Below Targeting the toughest to treat Dravet... Read more
17d
FOX Business
Why GW Pharmaceuticals, Louisiana-Pacific, and IAMGOLD Slumped Todaysuccessful clinical trial by one of the company's rivals. The cannabinoid treat
FOX Business / Posted 17 days ago
successful clinical trial by one of the company's rivals. The cannabinoid treatment specialist has been looking to use its Epidiolex lead candidate drug to fight severe epilepsy syndromes such as Dravet syndrome, and investors have been optimistic... Read more
3 related articles
17d
FOX Business
Why GW Pharmaceuticals, Louisiana-Pacific, and IAMGOLD Slumped Todaysuccessful clinical trial by one of the company's rivals. The cannabinoid treat
FOX Business / Posted 17 days ago
successful clinical trial by one of the company's rivals. The cannabinoid treatment specialist has been looking to use its Epidiolex lead candidate drug to fight severe epilepsy syndromes such as Dravet syndrome, and investors have been optimistic... Read more
3 related articles
17d
FOX Business
Why Zogenix Inc. Stock More Than Doubled TodayGWPH) is reportedly putting the finishing touches on a regulatory application f
FOX Business / Posted 17 days ago
GWPH) is reportedly putting the finishing touches on a regulatory application for its own candidate drug, called Epidiolex. Not surprisingly, GW Pharmaceuticals stock dropped by as much as 15% in pre-market trading as a result of the news... Read more
3 related articles
17d
FOX Business
Why Zogenix Inc. Stock More Than Doubled TodayGWPH) is reportedly putting the finishing touches on a regulatory application f
FOX Business / Posted 17 days ago
GWPH) is reportedly putting the finishing touches on a regulatory application for its own candidate drug, called Epidiolex. Not surprisingly, GW Pharmaceuticals stock dropped by as much as 15% in pre-market trading as a result of the news... Read more
3 related articles
18d
FOX Business
Should You Invest in This Marijuana ETF?by the FDA like any other prescription drug. GW Pharmaceuticals has already po
FOX Business / Posted 18 days ago
by the FDA like any other prescription drug. GW Pharmaceuticals has already posted positive clinical trial results for Epidiolex, which contains cannabidiol derived from marijuana, in patients with two rare types of epilepsy, Dravet syndrome... Read more
18d
FOX Business
Should You Invest in This Marijuana ETF?by the FDA like any other prescription drug. GW Pharmaceuticals has already po
FOX Business / Posted 18 days ago
by the FDA like any other prescription drug. GW Pharmaceuticals has already posted positive clinical trial results for Epidiolex, which contains cannabidiol derived from marijuana, in patients with two rare types of epilepsy, Dravet syndrome... Read more
22d
FOX Business
3 Top Marijuana Stocks to Buy This Fallfor this cannabinoid-focused biotech, though. GW Pharma expects to complete it
FOX Business / Posted 22 days ago
for this cannabinoid-focused biotech, though. GW Pharma expects to complete its U.S. regulatory submission for cannabidiol Epidiolex for treating Dravet syndrome and Lennox-Gastaut syndrome in October. The company also anticipates submitting... Read more
22d
FOX Business
3 Top Marijuana Stocks to Buy This Fallfor this cannabinoid-focused biotech, though. GW Pharma expects to complete it
FOX Business / Posted 22 days ago
for this cannabinoid-focused biotech, though. GW Pharma expects to complete its U.S. regulatory submission for cannabidiol Epidiolex for treating Dravet syndrome and Lennox-Gastaut syndrome in October. The company also anticipates submitting... Read more
24d
New Kerala
Advances in Drug Delivery Hold the Promise of Reducing Inevitable Side Effects - newkerala news #274262product, Sativex, is working feverishly to bring another to market. Currently,
New Kerala / Posted 24 days ago
product, Sativex, is working feverishly to bring another to market. Currently, its lead cannabinoid product candidate Epidiolex is in phase III clinical trials. This drug is a proprietary oral solution of pure plant-derived cannabidiol (CBD)... Read more
29d
FOX Business
5 Marijuana Stocks Overflowing With CashFirst, GW Pharmaceuticals is preparing for what it expects could be a costly bu
FOX Business / Posted 29 days ago
First, GW Pharmaceuticals is preparing for what it expects could be a costly but lucrative launch of experimental drug Epidiolex, an oral cannabidiol-based medicine designed to treat two rare types of childhood-onset epilepsy -- Dravet syndrome... Read more
3 related articles
29d
FOX Business
5 Marijuana Stocks Overflowing With CashFirst, GW Pharmaceuticals is preparing for what it expects could be a costly bu
FOX Business / Posted 29 days ago
First, GW Pharmaceuticals is preparing for what it expects could be a costly but lucrative launch of experimental drug Epidiolex, an oral cannabidiol-based medicine designed to treat two rare types of childhood-onset epilepsy -- Dravet syndrome... Read more
3 related articles
29d
FOX Business
Jeff Sessions May Soon Have a Green Light to Wage War on Medical-Marijuana BusinessesGWPH), which is the largest marijuana stock by market cap, has had incredible s
FOX Business / Posted 29 days ago
GWPH), which is the largest marijuana stock by market cap, has had incredible success with its lead developing drug Epidiolex. In multiple late-stage studies involving two rare types of childhood-onset epilepsy, this oral cannabidiol-based... Read more
3 related articles
29d
FOX Business
Jeff Sessions May Soon Have a Green Light to Wage War on Medical-Marijuana BusinessesGWPH), which is the largest marijuana stock by market cap, has had incredible s
FOX Business / Posted 29 days ago
GWPH), which is the largest marijuana stock by market cap, has had incredible success with its lead developing drug Epidiolex. In multiple late-stage studies involving two rare types of childhood-onset epilepsy, this oral cannabidiol-based... Read more
3 related articles
m
FOX Business
Investors' Biggest Worry About GW Pharmaceuticals Could Be the Biotech's Ace in the Holeperformance is that some investors are worried about the impact of drug-drug in
FOX Business / Posted 1 months ago
performance is that some investors are worried about the impact of drug-drug interactions with the company's lead candidate Epidiolex. Continue Reading Below Executives from GW Pharma had the opportunity to discuss Epidiolex and investors'... Read more

In this news